Arsenic in Groundwater
On this page
Direct answer
Bangladesh's tube-well catastrophe of the 1990s had an Indian twin: alluvial aquifers of the Ganga-Brahmaputra basin — West Bengal above all, with Bihar, Uttar Pradesh, Assam and Jharkhand, plus pockets elsewhere — leach geogenic arsenic into the deep drinking-water wells that replaced surface sources, exposing millions chronically. India's drinking-water standard, aligned with WHO, is 10 micrograms per litre (0.01 parts per million), replacing the older 50 microgram limit, and the clinical signature of chronic exposure is arsenicosis: raindrop pigmentation of the trunk, palmar-plantar keratosis, and — over decades — skin cancers including Bowen's disease, plus elevated risks of lung and bladder cancer, peripheral vascular disease and diabetes. Diagnosis rests on exposure history with hair, nail and urine arsenic; management is essentially removal from exposure, since chronic arsenicosis has no established specific therapy, which is why mitigation — water testing, safe alternatives, treatment units — is the entire public health game.
What you must remember
- Standard to quote: Bureau of Indian Standards acceptable limit 10 micrograms per litre (WHO guideline value the same), with 50 micrograms permissible only as a reluctant interim in the absence of any alternative source.
- Geography: the Bengal basin is the epicentre — a large number of affected blocks across West Bengal's districts — with the middle Ganga plain (Bihar, eastern Uttar Pradesh, Jharkhand) and Assam following; Chhattisgarh and pockets in Punjab add scattered foci.
- Cause: naturally occurring arsenic in alluvial sediments dissolving into anoxic aquifers — a geogenic, not industrial, contamination; deep tube wells replaced dug wells and pulled the problem up.
- Cutaneous signature: melanosis in a raindrop pattern, keratotic papules on palms and soles; later Bowen's disease, squamous and basal cell carcinomas — arsenic is an IARC Group 1 human carcinogen.
- Systemic disease: chronic exposure associates with lung and bladder cancer, peripheral vascular disease (blackfoot disease in the Taiwanese literature), hypertension, and diabetes; Mee's lines on nails mark systemic exposure.
- Diagnosis: water testing first; biological monitoring via urine (recent exposure) and hair or nail (past months of exposure) arsenic levels; the patient without a water-test result is a hypothesis, not a case.
- Management axiom: stop exposure — alternative safe source (deep aquifer tested, piped supply, rainwater harvesting), arsenic removal units (for example activated alumina); chelation has no established role in chronic arsenicosis.
One village's slow discovery
A tube well sunk in the 1980s yields clear, sweet water; two decades later, adults in a cluster of households show dark, raindrop stippling over the trunk and gritty palms, and a dermatologist's referral letter says "pigmentation, ? cause". The block's water testing finds arsenic several times the 10 microgram standard; the primary health centre now registers arsenicosis cases, screens households sharing the well, and — critically — searches for skin lesions that could already be early cancer. The mitigation menu unfolds: an alternative tested source, an arsenic removal unit with a maintenance contract (units fail when media is never regenerated), rainwater harvesting for monsoon months. Nothing reverses the keratosis; everything depends on cutting exposure before the malignancies arrive.
The population lesson is the health-services angle examiners reward: arsenicosis is a slow, multi-system disease with a purely environmental cure, so the clinician's role is case definition (surveillance criteria require pigmentation or keratosis plus confirmed water exposure), the public health engineer's role is water, and neither succeeds alone. Contrast the twin geogenic contaminant, fluoride — dental and skeletal fluorosis in a different geological belt — because a theory answer that compares the two geogenic poisonings reads as understanding rather than recall.
How the exam frames it
Short-note questions ask for "arsenicosis" or "arsenic contamination of groundwater", and the mark distribution favours: source and geography, standard (10 micrograms per litre), clinical stages in order, cancer risk, and mitigation hierarchy. The classic trap is drinking-water numerics: 10 is arsenic's limit in micrograms per litre, while fluoride's is 1.0 milligram per litre — mixing units is the quickest route to a wrong answer. Second trap: calling it industrial pollution — the Indian problem is geological, released into aquifers tapped for "safe" water, which is precisely the public-health irony worth stating. Viva probes include why hair and nail samples serve as long-term exposure markers (arsenic binds keratin) and why chelation is not the answer in chronic disease. A differentiating detail: National Green Tribunal and Jal Jeevan Mission-era water-quality surveillance have pushed universal testing — a current-affairs hook that dates the answer to the present decade.
Frequently asked questions
What is the permissible arsenic level in Indian drinking water?
The acceptable Bureau of Indian Standards limit is 10 micrograms per litre, matching the WHO guideline, with 50 micrograms permitted only as an interim where no alternative source exists.
Which states bear the main arsenic burden?
West Bengal is the epicentre, followed by Bihar, Uttar Pradesh, Jharkhand and Assam in the Ganga-Brahmaputra basin, with scattered foci such as Chhattisgarh and parts of Punjab.
What are the early cutaneous signs of chronic arsenicosis?
Raindrop-pattern pigmentation of the trunk and keratosis of the palms and soles — the lesions that surveillance case definitions are built on, preceding cancers by years.
Is arsenic a proven human carcinogen?
Yes, IARC lists arsenic as a Group 1 carcinogen, causally linked to skin cancer (including Bowen's disease), lung cancer and bladder cancer among chronically exposed populations.
How is chronic arsenicosis managed?
By removing exposure — shifting to a tested safe source or treated water — with surveillance for premalignant lesions; there is no established specific drug therapy for chronic arsenicosis.